GlobeNewswire
-
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®
16/11/2026 -
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
16/11/2026 -
Mesoblast Showcased at ASX Premier Investor Day Event
16/11/2026 -
Helus Pharma to Present Topline Results from Phase 3 APPROACH Study Evaluating HLP003 as Adjunctive Treatment in Major Depressive Disorder on November 16, 2026
15/11/2026 -
Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results
15/11/2026 -
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
15/11/2026 -
NeuroKaire To Showcase Breakthrough Blood Test That Ends the Antidepressant Guessing Game at HLTH 2026 Conference
15/11/2026 -
Grassroot Soccer Honors U.S. Soccer at 2026 Gala, Raising over $2 million for Adolescent Health Programs
15/11/2026 -
Keto-Mojo Unveils World’s First Photoacoustic Breathalyzer, Advancing Non-Invasive Ketone Monitoring
14/11/2026 -
Oban BioPharma Announces Presentation of Late-Breaking Abstract at Obesity Week® 2026
14/11/2026 -
Prolynx Presents Preclinical Data at ObesityWeek® 2026 Supporting the Potential for Quarterly Dosing of Ultra-Long-Acting Anti-Obesity Peptides
14/11/2026 -
Quantum-Si Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
14/11/2026 -
Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress
13/11/2026 -
BeyondSpring Reports Third-Quarter 2026 Financial Results and Provides Corporate Update
13/11/2026 -
Calidi Biotherapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
13/11/2026 -
Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
13/11/2026 -
Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
13/11/2026 -
Natural Alternatives International, Inc. Announces Fiscal 2027 Q1 Results
13/11/2026 -
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
13/11/2026
Pages